Document is current
Any future updates will be listed below
-
Authors
Julian, Thomas H. https://orcid.org/0000-0002-5488-5620
Dou, Haoran https://orcid.org/0000-0001-8628-5489
Duan, Jinming
Huang, Jinghan
Yoo, Esther https://orcid.org/0000-0001-8759-0098
Green, David J.
Strange, Andrew https://orcid.org/0000-0002-2004-150X
Alhathli, Elham https://orcid.org/0009-0008-2147-9715
Sperrin, Matthew https://orcid.org/0000-0002-5351-9960
Keane, Pearse A. https://orcid.org/0000-0002-9239-745X
Chew, Emily Y. https://orcid.org/0000-0003-0999-9802
Keavney, Bernard https://orcid.org/0000-0001-9573-0812
Fitzgerald, Tomas W. https://orcid.org/0000-0002-2370-8496
Cooper-Knock, Johnathan https://orcid.org/0000-0002-0873-8689
Birney, Ewan https://orcid.org/0000-0001-8314-8497
Frangi, Alejandro F. https://orcid.org/0000-0002-2675-528X
Sergouniotis, Panagiotis I. https://orcid.org/0000-0003-0986-4123
,
- License Information
-
More Information
Article History
Received: 20 August 2025
Accepted: 30 March 2026
First Online: 16 June 2026
Competing interests
: P.A.K. is a cofounder of Cascader Ltd. and has acted as a consultant for insitro, Retina Consultants of America, Roche, Boehringer-Ingleheim and Bitfount and is an equity owner in Big Picture Medical. He has received speaker fees from Zeiss, Thea, Apellis and Roche and grant funding from Roche. He has received travel support from Bayer and Roche. He has attended advisory boards for Topcon, Bayer, Boehringer-Ingleheim and Roche. A.F.F. is cofounder and NED of OculomeX Health Ltd and adsilico Ltd and has acted as a consultant for these companies. The other authors declare no competing interests.
